TrakGene clinical data management database used in the 10 year CAPP2 research trial into cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome)

In June 2020 the findings of a 10 year international clinical study, known as CAPP2, were published. The study follows patients with Lynch Syndrome, a genetic condition that leaves them at higher risk of development bowel cancer. The purpose of the study is to determine whether a daily dose of aspirin can be used to reduce the risk of bowel cancer.

The research is led by Professor Sir John Burn. TrakGene have worked with the research team to help them, with TrakGene providing the clinical data management database required to collate the data used in the CAPP2 study. We are delighted that the TrakGene database software has been used successfully on such an important study and to see that the data conversion work we did with the CAPP2 team a number of years ago has paid dividends.

Using TrakGene as a clinical data management database is just one of the features of our software solution, more of which can be discovered here on our TrakGene Features page. CAPP2 is one of a number of clinical research studies that use TrakGene to mange their clinical research data.

The CAPP2 study has been able to publish it’s findings that a single daily dose of aspirin was effective in the long-term prevention of colorectal cancer. The full publication has been published on The Lancet and is available from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30366-4/fulltext 

The study now continues into its next phase, CaPP3, to study the optimum does of aspirin to prevent colorectal cancer in people with Lynch Syndrome. We look forward to continue to support the research study’s use of TrakGene as their chosen clinical data management database and wish them every success with the next phase of the study.